Article

FDA clears hybrid digital retinal camera

The FDA has granted 510(k) clearance to a hybrid mydriatic/non-mydriatic digital retinal camera (CX-1, Canon).

Lake Success, NY

-The FDA has granted 510(k) clearance to a hybrid mydriatic/non-mydriatic digital retinal camera (CX-1, Canon).

The device is the company’s first fully hybrid digital retinal camera with both mydriatic and non-mydriatic modes and is designed to enable the operator to switch automatically between modes with one touch. The camera also is designed to allow the user to perform one-shot fundus autofluorescence (FAF) photography in a standard configuration, for both mydriatic and non-mydriatic modes. In addition to FAF modes, the single onboard digital camera handles color, red-free, and cobalt modes.

“Canon’s latest advancement . . . will help eye-care professionals provide comprehensive, high-end care to their patients by providing outstanding digital imaging technology,” said Tsuneo Imai, senior director and general manager, Medical Systems Division, Canon U.S.A.

Additionally, according to the company:

• The camera features proprietary technology adapted exclusively for medical use, providing up to 15.1-megapixel resolution.
• The camera is capable of delivering diagnostic images for virtually immediate review.
• The camera also comes with PC-based retinal imaging control software designed to put comprehensive study management, image capture controls, and easy viewing at the user’s fingertips. It includes a graphical interface that is designed to be intuitive, simple, and straightforward. The software is designed to provide quick input and access to information and images required to assist in patient diagnosis. Data can be saved to various external media.

The camera is available through authorized dealers.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.